In the news · TODAY & NBC News · October 7, 2026
Exclusive: Novel Vaccine Shows Promise Against Brain Cancer
TODAY and NBC News report on SurVaxM, the investigational immunotherapy MimiVax is developing for glioblastoma.
← Back to News & Resources
Interested in access to SurVaxM? SURVIVE has completed enrollment and no SurVaxM glioblastoma studies are currently enrolling. Patients and caregivers can learn about expanded access, and how to make a request through a treating physician, on the Expanded Access page.
Video and reporting courtesy of TODAY and NBC News. SurVaxM is an investigational product. It has not been approved by the FDA or any other regulatory authority. Information on this site is intended for healthcare professionals, researchers and industry partners.